Today’s Money Reporter Kim Gun-woo | 2023.06.14 10:31
Medifron, a research company on the treatment of Alzheimer’s disease, announced on the 14th that it has acquired a domestic patent for an O-GlcNAcase (OGA) inhibitor (MDR-0214), a leading substance for the treatment of Alzheimer’s disease.
OGA inhibitors are substances that prevent the denaturation and aggregation of tau protein, which is known to be the main cause of Alzheimer’s disease. The company explained that recent studies at home and abroad show the relationship between the mechanism of OGA, the target of MDR-0214, the process of tau protein phosphorylation, the program of nerve cell death (necroptosis), and degenerative diseases.
Lim Jae-hong, director of the research institute, said, “Through this patent registration, we have been able to receive recognition for our research achievements and officially secure the technology.” We will do our best to become a leading company.”
Medipron’s independent development and joint application with Seoul National University have registered 7 patents related to dementia treatment, including ‘MDR-1339’. In addition, using registered patents, they prepare for development research such as dementia treatment, inflammation control, and mechanism control by preventing tau protein change.
Meanwhile, Medipron successfully completed a phase 1 clinical trial of ‘MDR-652’, a non-narcotic pain reliever that acts on neuropathic pain, in March. The company said, “We are reviewing various future directions, including out-licensing with global pharmaceutical companies, until new drugs are released in the future.”
In addition, the dementia early diagnosis kit, which is being developed in collaboration with Quanta Matrix, a company specializing in in vitro diagnostics through a license out in 2020, is in the process of preparing for registration as a medical technology new after certification of an item by the Ministry. Food and Drug Safety.
[저작권자 @머니투데이, 무단전재 및 재배포 금지]